Skip to content
Murepavadin / Studies
Synthetic analog · 14 amino acids · 1,553.8 Da

Murepavadin studies and research data

PepBank has 21 murepavadin studies with results. 18 of them gave murepavadin, with 62 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 62 results and 44 papers. Newer studies from Europe PMC

Results in people
11
18% of 62 results
Results in animals
6
10% of 62 results
Results in lab cells
45
73% of 62 results
From computer models
0
0% of 62 results
The molecule

Murepavadin identity

Identifiers, parent molecule, targets and development stage, from curated data.

Murepavadin is a synthetic cyclic beta-hairpin peptidomimetic based on protegrin I. It inhibits bacterial LptD and is studied against Pseudomonas aeruginosa. The intravenous phase 3 PRISM studies stopped in 2019 after a kidney injury signal. The current sponsor describes the inhaled formulation as phase 2 ready.

Kind
Synthetic analog · 14 residues
Identifiers
ChEMBLCHEMBL3946483 (opens in a new tab)PubChem CID91824766 (opens in a new tab)UNII0D02GRY87Z (opens in a new tab)DrugBankDB14777 (opens in a new tab)CAS944252-63-5KEGGD10957 (opens in a new tab)IUPHAR10832 (opens in a new tab)
Development
Phase 3Polyphor / Spexis (historical), Cyaris (current sponsor website)Intravenous phase 3 PRISM studies stopped in July 2019 after higher than expected acute kidney injury. Historical highest phase remains phase 3. The current Cyaris website describes inhaled murepavadin as phase 2 ready. This does not establish active recruitment. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
TargetActionEvidence
Lipopolysaccharide transport protein D (LptD)lptDInhibitorPrimary human pharmacokinetic study describes LptD binding and inhibition of lipopolysaccharide transport.Source (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

Sequence not disclosed

FDA GSRS establishes the cyclic 14-residue sequence, D-Pro3 and D-Dab10. Other residues have the stated L or (2S) configuration. Dab means 2,4-diaminobutyric acid. No free termini or disulfide bonds occur. Properties describe the parent compound without a salt counterion. The one-letter sequence and HELM remain null because no standardized encoding was verified.

Properties

From identity sources

Formula
C73H112N22O16
Molecular weight
1,553.8 g/mol
Monoisotopic mass
1,552.8627 Da

Calculated from the sequence

No sequence is listed, so nothing can be calculated.

Net charge by pH

No charge curve

No sequence is listed for this peptide.

Composition

No sequence is listed for this peptide.

3D structure

No 3D structure

No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 91824766(opens in a new tab)

CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N2CCC[C@@H]2C(=O)N3CCC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CC4=CNC5=CC=CC=C54)[C@@H](C)O)CO)C)CCN)CCN)CC6=CNC7=CC=CC=C76)CCN)CCN)CCCN)CCN
Results by area

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Trials and papers
Status and safety
Data